{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:41:27Z","timestamp":1789767687002,"version":"4.0.1"},"reference-count":40,"publisher":"China Science Publishing & Media Ltd.","issue":"10","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2016,10,1]]},"DOI":"10.1093\/abbs\/gmw082","type":"journal-article","created":{"date-parts":[[2016,9,3]],"date-time":"2016-09-03T03:40:16Z","timestamp":1472874016000},"page":"894-901","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non&amp;ndash;small-cell lung carcinoma and malignant mesothelioma"],"prefix":"10.3724","volume":"48","author":[{"given":"Ruling","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danrong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2016,10,1]]},"reference":[{"key":"null","first-page":"169","volume":"21","author":"Darzynkiewicz Z","year":"1988","unstructured":"Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K. Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet, 1988, 21: 169-182.","journal-title":"Cell Tissue Kinet"},{"key":"null","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejphar.2009.06.067","volume":"625","author":"Ardelt W","year":"2009","unstructured":"Ardelt W, Ardelt B, Darzynkiewicz Z. Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol, 2009, 625: 181-189.","journal-title":"Eur J Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/febs.12406","volume":"280","author":"Hacke M","year":"2013","unstructured":"Hacke M, Gruber T, Schulenburg C, Balbach J, Arnold U. Consequences of proline-to-alanine substitutions for the stability and refolding of onconase. FEBS J, 2013, 280: 4454-4462.","journal-title":"FEBS J"},{"key":"null","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1073\/pnas.95.18.10407","volume":"95","author":"Leland PA","year":"1998","unstructured":"Leland PA, Schultz LW, Kim BM, Raines RT. Ribonuclease A variants with potent cytotoxic activity. Proc Natl Acad Sci USA, 1998, 95: 10407-10412.","journal-title":"Proc Natl Acad Sci USA"},{"key":"null","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/nar\/gkg163","volume":"31","author":"Haigis MC","year":"2003","unstructured":"Haigis MC, Kurten EL, Raines RT. Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res, 2003, 31: 1024-1032.","journal-title":"Nucleic Acids Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/sj.leu.2401100","volume":"12","author":"Juan G","year":"1998","unstructured":"Juan G, Ardelt B, Li X, Mikulski SM, Shogen K, Ardelt W, Mittelman A. G1 arrest of U937 cells by onconase is associated with suppression of cyclin D3 expression, induction of p16INK4A, p21WAF1\/CIP1 and p27KIP and decreased pRb phosphorylation. Leukemia, 1998, 12: 1241-1248.","journal-title":"Leukemia"},{"key":"null","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1016\/S0021-9258(18)82252-9","volume":"268","author":"Wu Y","year":"1993","unstructured":"Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem, 1993, 268: 10686-10693.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"15142","DOI":"10.1074\/jbc.M108115200","volume":"277","author":"Saxena SK","year":"2002","unstructured":"Saxena SK, Sirdeshmukh R, Ardelt W, Mikulski SM, Shogen K, Youle RJ. Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem, 2002, 277: 15142-15146.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/onc.2010.643","volume":"30","author":"Goparaju CM","year":"2011","unstructured":"Goparaju CM, Blasberg JD, Volinia S, Palatini J, Ivanov S, Donington JS, Croce C. Onconase mediated NFKbeta downregulation in malignant pleural mesothelioma. Oncogene, 2011, 30: 2767-2777.","journal-title":"Oncogene"},{"key":"null","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/cr.2012.67","volume":"22","author":"Qiao M","year":"2012","unstructured":"Qiao M, Zu LD, He XH, Shen RL, Wang QC, Liu MF. Onconase downregulates microRNA expression through targeting microRNA precursors. Cell Res, 2012, 22: 1199-1202.","journal-title":"Cell Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2407-10-34","volume":"10","author":"Altomare DA","year":"2010","unstructured":"Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC Cancer, 2010, 10:","journal-title":"BMC Cancer"},{"key":"null","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO.2002.20.1.274","volume":"20","author":"Mikulski SM","year":"2002","unstructured":"Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, Chun H, Mittelman A. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol, 2002, 20: 274-281.","journal-title":"J Clin Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10637-012-9873-z","volume":"31","author":"Lai HC","year":"2013","unstructured":"Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs, 2013, 31: 230-246.","journal-title":"Invest New Drugs"},{"key":"null","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/2141-9248.153609","volume":"5","author":"Das AK","year":"2015","unstructured":"Das AK. Anticancer effect of antimalarial artemisinin compounds. Ann Med Health Sci Res, 2015, 5: 93-102.","journal-title":"Ann Med Health Sci Res"},{"key":"null","first-page":"247597","volume":"2012","author":"Crespo-Ortiz MP","year":"2012","unstructured":"Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol, 2012, 2012:","journal-title":"J Biomed Biotechnol"},{"key":"null","first-page":"123","volume":"33","author":"Gong Y","year":"2013","unstructured":"Gong Y, Gallis BM, Goodlett DR, Yang Y, Lu H, Lacoste E, Lai H. Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines. Anticancer Res, 2013, 33: 123-132.","journal-title":"Anticancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1039\/C4NP00130C","volume":"32","author":"AlQathama A","year":"2015","unstructured":"AlQathama A, Prieto JM. Natural products with therapeutic potential in melanoma metastasis. Nat Prod Rep, 2015, 32: 1170-1182.","journal-title":"Nat Prod Rep"},{"key":"null","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00280-003-0751-4","volume":"53","author":"Chen HH","year":"2004","unstructured":"Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol, 2004, 53: 423-432.","journal-title":"Cancer Chemother Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.bcp.2004.08.021","volume":"68","author":"Dell'Eva R","year":"2004","unstructured":"Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol, 2004, 68: 2359-2366.","journal-title":"Biochem Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00280-005-0002-y","volume":"57","author":"Lee J","year":"2006","unstructured":"Lee J, Zhou HJ, Wu XH. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother Pharmacol, 2006, 57: 213-220.","journal-title":"Cancer Chemother Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10637-008-9188-2","volume":"27","author":"Buommino E","year":"2009","unstructured":"Buommino E, Baroni A, Canozo N, Petrazzuolo M, Nicoletti R, Vozza A, Tufano MA. Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs, 2009, 27: 412-418.","journal-title":"Invest New Drugs"},{"key":"null","first-page":"1599","volume":"14","author":"Berger TG","year":"2005","unstructured":"Berger TG, Dieckmann D, Efferth T, Schultz ES, Funk JO, Baur A, Schuler G. Artesunate in the treatment of metastatic uveal melanoma\u2014first experiences. Oncol Rep, 2005, 14: 1599-1603.","journal-title":"Oncol Rep"},{"key":"null","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1534735406295311","volume":"5","author":"Singh NP","year":"2006","unstructured":"Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther, 2006, 5: 391-394.","journal-title":"Integr Cancer Ther"},{"key":"null","first-page":"4417","volume":"31","author":"Jansen FH","year":"2011","unstructured":"Jansen FH, Adoubi I, JC KC, DE Cnodder T, Jansen N, Tschulakow A, Efferth T. First study of oral Artenimol-R in advanced cervical cancer: clinical benefit, tolerability and tumor markers. Anticancer Res, 2011, 31: 4417-4422.","journal-title":"Anticancer Res"},{"key":"null","first-page":"901","volume":"29","author":"Shen R","year":"2007","unstructured":"Shen R, Sun R, Wang Q, Ou L, Fei J. Growth inhibition effect of Onconase on B16 melanoma cells in vitro and in vivo. Chin J Cell Biol, 2007, 29: 901-904.","journal-title":"Chin J Cell Biol"},{"key":"null","first-page":"943","volume":"47","author":"Carmichael J","year":"1987","unstructured":"Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res, 1987, 47: 943-946.","journal-title":"Cancer Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"Chou TC","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984, 22: 27-55.","journal-title":"Adv Enzyme Regul"},{"key":"null","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ptr.2472","volume":"22","author":"Hou W","year":"2008","unstructured":"Hou W, Chen L, Yang G, Zhou H, Jiang Q, Zhong Z, Hu J. Synergistic antitumor effects of liposomal honokiol combined with adriamycin in breast cancer models. Phytother Res, 2008, 22: 1125-1132.","journal-title":"Phytother Res"},{"key":"null","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/jnci\/djq457","volume":"102","author":"Shim JS","year":"2010","unstructured":"Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst, 2010, 102: 1855-1873.","journal-title":"J Natl Cancer Inst"},{"key":"null","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1074\/jbc.M110.144188","volume":"286","author":"Mercer AE","year":"2011","unstructured":"Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem, 2011, 286: 987-996.","journal-title":"J Biol Chem"},{"key":"null","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acschembio.5b01043","volume":"11","author":"Zhou Y","year":"2016","unstructured":"Zhou Y, Li W, Xiao Y. Profiling of multiple targets of artemisinin activated by hemin in cancer cell proteome. ACS Chem Biol, 2016, 11: 882-888.","journal-title":"ACS Chem Biol"},{"key":"null","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<164::AID-JSO10>3.0.CO;2-2","volume":"73","author":"Lee I","year":"2000","unstructured":"Lee I, Lee YH, Mikulski SM, Lee J, Covone K, Shogen K. Tumoricidal effects of onconase on various tumors. J Surg Oncol, 2000, 73: 164-171.","journal-title":"J Surg Oncol"},{"key":"null","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.vph.2007.05.002","volume":"47","author":"Zhou HJ","year":"2007","unstructured":"Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol, 2007, 47: 131-138.","journal-title":"Vascul Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000148261","volume":"82","author":"Wang J","year":"2008","unstructured":"Wang J, Zhang B, Guo Y, Li G, Xie Q, Zhu B, Gao J. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology, 2008, 82: 148-155.","journal-title":"Pharmacology"},{"key":"null","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00280-009-1129-z","volume":"66","author":"Zhou HJ","year":"2010","unstructured":"Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother Pharmacol, 2010, 66: 21-29.","journal-title":"Cancer Chemother Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1211\/jpp.59.6.0011","volume":"59","author":"Huang XJ","year":"2007","unstructured":"Huang XJ, Ma ZQ, Zhang WP, Lu YB, Wei EQ. Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol, 2007, 59: 849-856.","journal-title":"J Pharm Pharmacol"},{"key":"null","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nature06905","volume":"453","author":"Rius J","year":"2008","unstructured":"Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 2008, 453: 807-811.","journal-title":"Nature"},{"key":"null","doi-asserted-by":"crossref","first-page":"e1001285","DOI":"10.1371\/journal.pgen.1001285","volume":"7","author":"van Uden P","year":"2011","unstructured":"van Uden P, Kenneth NS, Webster R, Muller HA, Mudie S, Rocha S. Evolutionary conserved regulation of HIF-1beta by NF-kappaB. PLoS Genet, 2011, 7:","journal-title":"PLoS Genet"},{"key":"null","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1242\/jcs.00286","volume":"116","author":"Kiriakidis S","year":"2003","unstructured":"Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci, 2003, 116: 665-674.","journal-title":"J Cell Sci"},{"key":"null","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.tibs.2007.06.005","volume":"32","author":"Rocha S","year":"2007","unstructured":"Rocha S. Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem Sci, 2007, 32: 389-397.","journal-title":"Trends Biochem Sci"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/8B7D47CA59FD41BDB5D0B220A3877AD0","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmw082","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/engine.scichina.com\/doi\/pdf\/8B7D47CA59FD41BDB5D0B220A3877AD0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T05:43:33Z","timestamp":1718775813000},"score":1,"resource":{"primary":{"URL":"http:\/\/engine.scichina.com\/doi\/10.1093\/abbs\/gmw082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,1]]},"published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abbs\/gmw082","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,1]]}}}